BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Beijing Tide Begins Phase II Trial of First-in-Class Non-Opioid CPSP Drug TRD205

Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class ...

May 06, 2025 | News

Fangzhou Launches Otsuka’s Iclusig® Online for Leukemia Care in China

Fangzhou Inc. , a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhi...

May 06, 2025 | News

Nutshell Therapeutics Receives FDA IND Clearance for First-in-Human Trial of NTS071 Targeting p53 Y220C Mutation

Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical ...

May 05, 2025 | News

InnoCare’s Zurletrectinib Granted Priority Review in China for NTRK Fusion-Positive Solid Tumors

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that its new genera...

May 05, 2025 | News

JediCare, West China Hospital Complete First Human Study of Percutaneous Nodule Resection Device

JediCare Medical Technology Co., Ltd. a Shanghai, China based company ("the Company"), jointly with West China Hospital of Sichuan Univ...

May 02, 2025 | News

Innovent Biologics Doses First Patient in Global Phase 1 Trial of IBI3020, a First-in-Class Dual-Payload CEACAM5 ADC

Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment ...

April 30, 2025 | News

Keymed Biosciences Advances CDH17-Targeted ADC CM518D1 Into Phase I/II Trials for Solid Tumors in China

Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) develop...

April 28, 2025 | News

Innovent Biologics Secures NMPA Approval for Limertinib as First-Line Therapy for EGFR-Mutated NSCLC in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

April 28, 2025 | News

Doer Bio Begins Phase 2 Trial of Tri-Agonist DR10624 for MASLD and MASH Treatment

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...

April 24, 2025 | News

Sichuan Kelun-Biotech Secures FDA IND Clearance for First-in-Class ADC SKB518

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new dru...

April 22, 2025 | News

Rona Therapeutics Secures IND Approval in China for siRNA-Based Hypertension Therapy RN1871

Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for&...

April 22, 2025 | News

China Rises as Global Force in Blood Purification Tech at BPPC Annual Conference

Blood Purification Professional Committee (BPPC) of the China Medical Device Industry Association (CMDIA) gathered in Liuyang, Hunan, for its annual c...

April 21, 2025 | News

Akeso Secures NMPA Approval for Ebdarokimab in Moderate-to-Severe Plaque Psoriasis

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, ...

April 21, 2025 | News

WuXi Biologics Achieves Asia’s First Commercial PPQ Milestone with 3 x 5,000L Single-Use Bioreactors

- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,0...

April 21, 2025 | News

Stay Connected